Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHF6001 add-on to maintenance triple therapy in COPD with chronic bronchitis
CTR20222968Phase 3Terminated
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tanimilast in chronic obstructive pulmonary disease (COPD), chronic bronchitis (CB), sponsored by Chiesi Farmaceutici S.p.A.. Started Apr 2023; status: terminated.
02
Drugs
tanimilast
03
Conditions
chronic obstructive pulmonary disease (COPD)chronic bronchitis (CB)
Beyond the preview
Go deeper on CTR20222968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222968.